NEW YORK, Feb. 27 - Bruker Daltonics and the Mayo Clinic have partnered to develop new methods for protein analysis using Fourier transform mass spectrometry, Bruker said today.
The collaboration between Bruker and David Muddiman, director of Mayo's W.M. Keck FT-ICR mass spec lab, is expected to "further develop the applications of ultra-high field FTMS," the partners said.
As part of the deal, Bruker has given the Mayo what is believed to be the world's first commercial 12 Tesla FTMS system, customized for proteome-wide measurements. In fact, Bruker today began installing the 12 Tesla superconducting magnet, a process that is scheduled to wrap up next month.
According to Bruker, the 12 Tesla APEX FTMS system will be Mayo's primary technology for studying the human proteome. "Our development of this ultra-high resolving power FTMS approach will help unravel the entire human proteome," Muddiman said in a statement. "There is simply nothing like ultra-high field FTMS anywhere else."
A modified Bruker Daltonics APEX FTMS system, equipped with a 9.4 Tesla superconducting magnet, has already been used at the DOE Pacific Northwest National Laboratory to characterize a bacterial proteome in 3 hours using accurate mass measurements and automated MS/MS.
Click here for more information.